Integra LifeSciences (NASDAQ:IART) Releases FY 2026 Earnings Guidance

Key Points

• FY 2026 guidance: Integra set EPS guidance of 2.400–2.500 (above the consensus 2.350) and revenue guidance of about $1.7 billion, roughly in line with estimates.
• Analyst sentiment is mixed to negative: the street shows 1 Buy, 3 Hold and 3 Sell ratings, an average "Reduce" rating and a consensus price target of $14.20 after several recent price cuts.
• Recent results and valuation: the company beat Q estimates with $0.54 EPS and $391.9M revenue, but shares trade near $10.65 with a market cap of roughly $830M and a trailing negative P/E.

Integra LifeSciences (NASDAQ:IART - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 2.400-2.500 for the period, compared to the consensus estimate of 2.350. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Citigroup decreased their price objective on shares of Integra LifeSciences from $11.00 to $9.00 and set a "sell" rating on the stock in a report on Wednesday, March 11th. Wall Street Zen lowered shares of Integra LifeSciences from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Truist Financial decreased their price objective on shares of Integra LifeSciences from $13.00 to $12.00 and set a "hold" rating on the stock in a report on Wednesday, April 15th. Weiss Ratings restated a "sell (e+)" rating on shares of Integra LifeSciences in a report on Friday, March 27th. Finally, Argus restated a "hold" rating on shares of Integra LifeSciences in a report on Wednesday, April 15th. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and a consensus price target of $14.20.

Integra LifeSciences Price Performance

Shares of IART opened at $10.65 on Tuesday. Integra LifeSciences has a fifty-two week low of $8.70 and a fifty-two week high of $16.49. The firm's 50 day moving average price is $10.09 and its 200 day moving average price is $11.73. The company has a market cap of $830.06 million, a P/E ratio of -1.58 and a beta of 1.08. The company has a quick ratio of 1.46, a current ratio of 2.54 and a debt-to-equity ratio of 1.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its earnings results on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm had revenue of $391.92 million for the quarter, compared to the consensus estimate of $381.81 million. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS. On average, research analysts forecast that Integra LifeSciences will post 2.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integra LifeSciences

Several large investors have recently added to or reduced their stakes in IART. Rubric Capital Management LP increased its stake in Integra LifeSciences by 58.4% during the 2nd quarter. Rubric Capital Management LP now owns 7,353,934 shares of the life sciences company's stock worth $90,233,000 after buying an additional 2,710,262 shares during the period. Paradigm Capital Management Inc. NY increased its position in shares of Integra LifeSciences by 57.5% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,181,500 shares of the life sciences company's stock valued at $26,767,000 after purchasing an additional 796,300 shares during the last quarter. Kotler Kevin purchased a new stake in shares of Integra LifeSciences in the 4th quarter valued at approximately $5,309,000. Soleus Capital Management L.P. increased its position in shares of Integra LifeSciences by 29.4% in the 2nd quarter. Soleus Capital Management L.P. now owns 1,387,818 shares of the life sciences company's stock valued at $17,029,000 after purchasing an additional 315,614 shares during the last quarter. Finally, J. Goldman & Co LP increased its position in shares of Integra LifeSciences by 30.8% in the 4th quarter. J. Goldman & Co LP now owns 1,243,772 shares of the life sciences company's stock valued at $15,448,000 after purchasing an additional 292,961 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.